论文部分内容阅读
目的 探讨p53、nm2 3基因在前列腺癌中的表达水平及肿瘤生物学行为和预后关系。方法 应用免疫组化S -P法对 33例前列腺癌和 1 8例前列腺增生症进行p53蛋白、nm2 3蛋白检测。结果 1 5例 (45 .5 % )前列腺癌呈p53蛋白阳性表达 ,前列腺增生症中p53蛋白无阳性表达。 2 4例 (72 .7% )前列腺癌和 1 6例 (88.9% )前列腺增生症呈nm2 3蛋白阳性表达。p53蛋白表达与前列腺癌的分化程度、肿瘤转移及 5年生存率密切相关 ,而与临床分期和复发无关。nm2 3蛋白阳性表达与前列腺癌临床分期、分化程度、肿瘤转移、复发及 5年生存率有关。结论 p53蛋白、nm2 3蛋白表达可作为临床判断前列腺癌预后的重要参考指标。
Objective To investigate the expression of p53 and nm23 gene in prostate cancer and the relationship between their biological behavior and prognosis. Methods Immunohistochemical S-P method for 33 cases of prostate cancer and 18 cases of benign prostatic hyperplasia p53 protein, nm23 protein detection. Results Fifteen cases (45.5%) had positive p53 protein expression in prostate cancer and no positive p53 protein expression in benign prostatic hyperplasia. 24 cases (72.7%) of prostate cancer and 16 cases (88.9%) of benign prostatic hyperplasia showed nm23 protein positive expression. p53 protein expression is closely related to the degree of differentiation, tumor metastasis and 5-year survival rate of prostate cancer, but not with the clinical stage and recurrence. The positive expression of nm23 protein correlated with the clinical stage, differentiation degree, tumor metastasis, recurrence and 5-year survival rate of prostate cancer. Conclusion The expression of p53 protein and nm23 protein can be used as an important reference for judging the prognosis of prostate cancer.